The latest research on nanocurcumin, lung inflammation, asthma and COPD and clinical studies.
A 2024 study examined the effects of nanocurcumin in moderate and severe COPD patients.
There was a reduction in inflammation (frequency of Th17 cells, mRNA expression, and cytokines secretion level of Th17-related factors)
Another larger study from 2024 reported that nanocurcumin
Increased lung function (FEV1, FVC and FEV1/FVC)
Reduce inflammation (decrease in IL-6 level)
A really interesting 2023 study examine the effects of nanocurcumin in people who smoked and reported that nanocurcumin supplementation could:
Decrease inflammation
Decreased oxidative stress
Comments